Malaria, Cerebral

• 

  Subject Areas on Research

  • A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. 
  • A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. 
  • Cerebrospinal Fluid Pterins, Pterin-Dependent Neurotransmitters, and Mortality in Pediatric Cerebral Malaria. 
  • Comparative efficacy of intramuscular artemether and intravenous quinine in Nigerian children with cerebral malaria. 
  • Complexity of the msp2 locus and the severity of childhood malaria, in south-western Nigeria. 
  • Developmental allometry and paediatric malaria. 
  • Elevated plasma phenylalanine in severe malaria and implications for pathophysiology of neurological complications. 
  • Glycocalyx breakdown is increased in African children with cerebral and uncomplicated falciparum malaria. 
  • IRGM3 contributes to immunopathology and is required for differentiation of antigen-specific effector CD8+ T cells in experimental cerebral malaria. 
  • Impaired systemic production of prostaglandin E2 in children with cerebral malaria. 
  • Impaired systemic tetrahydrobiopterin bioavailability and increased oxidized biopterins in pediatric falciparum malaria: association with disease severity. 
  • Index of suspicion. Case 1: Infant who has respiratory distress. Case 2: Abnormal behavior, seizures, and altered sensorium in a 7-year-old boy. Case 3: Fever and dysphagia in a 4-year-old girl. 
  • Interaction between acute diarrhoea and falciparum malaria in Nigerian children. 
  • Intraleucocytic malaria pigment and clinical severity of malaria in children. 
  • Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. 
  • Neurological features of cerebral malaria in Nigerian children. 
  • Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. 
  • Oral activated charcoal prevents experimental cerebral malaria in mice and in a randomized controlled clinical trial in man did not interfere with the pharmacokinetics of parenteral artesunate. 
  • Patchy ischemic retinal whitening. 
  • Quantification of Plasmodium falciparum histidine-rich protein-2 in cerebrospinal spinal fluid from cerebral malaria patients. 
  • Rapid increases in parasitemia following red cell exchange for malaria. 
  • Respiratory distress adversely affects the outcome of childhood cerebral malaria. 
  • Retinal haemorrhage in cerebral malaria. 
  • The clinical manifestations of cerebral malaria among Nigerian children with the sickle cell trait. 
  • [LMP-420, a new therapeutic approach for cerebral malaria?].